Comparative Pharmacology
Head-to-head clinical analysis: METRO I V versus METROGEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRO I V versus METROGEL.
METRO I.V. vs METROGEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole is a nitroimidazole antibiotic that exerts its bactericidal effect by entering bacterial cells and undergoing reduction by bacterial nitroreductases to form reactive intermediates that damage DNA, leading to cell death. It is selectively toxic to anaerobic bacteria and protozoa.
Metronidazole, after intracellular reduction, forms cytotoxic metabolites that disrupt bacterial DNA and inhibit nucleic acid synthesis. It also has anti-inflammatory and immunomodulatory effects in rosacea.
15-30 mg/kg IV loading dose, then 7.5-15 mg/kg IV every 6 hours. Typical adult dose: 500 mg IV every 6-8 hours.
Topical application of 1% gel: Apply a thin layer to affected area twice daily; intravaginal 0.75% gel: one applicatorful (5 g) once daily at bedtime.
None Documented
None Documented
8 hours (range 6-10 hours) in adults; prolonged to 12-24 hours in hepatic impairment.
8-10 hours (terminal); increased to 20-30 hours in hepatic impairment.
Renal: 60-80% unchanged; fecal: 6-15% (includes metabolites); biliary: minor contribution.
Renal: 60-80% as unchanged drug; fecal: 6-15%; biliary: minor.
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)